Scholarlink

Purpose <p>Muscle sympathetic nerve activity (MSNA) is valuable for managing postural tachycardia syndrome (POTS), but microneurography is clinically impractical. We investigated whether the Valsalva phase&#xa0;2 diastolic blood pressure rise (DBP<sub>VM2l_rise</sub>) serves as a sympathetic marker and proposed enhanced neurovascular transduction as a pathophysiological mechanism in hyperadrenergic POTS.</p> Methods <p>We included 21 POTS women and 22&#xa0;healthy women to perform Valsalva and microneurography. MSNA spike rate was obtained using stationary wavelet transformation. The DBP<sub>VM2l_rise</sub> cut point for hyperadrenergic POTS was optimized by the golden section search with its correlation to phase&#xa0;2 MSNA spike rate as an objective function. We defined peripheral sympathetic neurovascular transduction (psNVT) as a ratio of DBP<sub>VM2l_rise</sub> to early phase&#xa0;2 MSNA increase. We compared Valsalva responses between the identified hyperadrenergic and non-hyperadrenergic POTS.</p> Results <p>The DBP<sub>VM2l_rise</sub> strongly correlated with the Valsalva phase&#xa0;2 MSNA spike rate percentage change from baseline in healthy (<i>r</i> = 0.874, <i>p</i> &lt; 0.001). The DBP<sub>VM2l_rise</sub> cutoff criterion of 15&#xa0;mmHg optimally separated POTS into 7&#xa0;hyperadrenergic (≥ 15&#xa0;mmHg, <i>r</i> = 0.902, <i>p</i> = 0.014) and 14 non-hyperadrenergic (&lt; 15&#xa0;mmHg, <i>r</i> = 0.629, <i>p</i> = 0.021). Although similar MSNA spike rate, the hyperadrenergic group had higher baseline systolic blood pressure (118 ± 10 vs 105 ± 12&#xa0;mmHg, <i>p</i> = 0.026), shorter pressure recovery time (1.15 ± 0.75 vs 2.59 ± 1.17&#xa0;s, <i>p</i> = 0.048), and higher psNVT (2.60 ± 1.02 vs 0.58 ± 0.46&#xa0;mmHg/spike·s<sup>−1</sup>, <i>p</i> &lt; 0.001) than the non-hyperadrenergic POTS.</p> Conclusion <p>DBP<sub>VM2l_rise</sub> ≥ 15&#xa0;mmHg could be a sympathetic clinical marker and could identify hyperadrenergic POTS, characterized by enhanced neurovascular transduction despite comparable MSNA levels. This novel pathophysiological insight underscores the importance of sympathetic markers in POTS clinical management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyperadrenergic postural tachycardia syndrome associated with augmented neurovascular transduction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月14日

查看全文
  • Surat Kulapatana,
  • Luis E. Okamoto,
  • Stefano Rigo,
  • Vasile Urechie,
  • Thomas W. Cayton,
  • Ruijing E. Han,
  • Giris Jacob,
  • William D. Dupont,
  • Raffaello Furlan,
  • Italo Biaggioni,
  • André Diedrich

摘要

Purpose

Muscle sympathetic nerve activity (MSNA) is valuable for managing postural tachycardia syndrome (POTS), but microneurography is clinically impractical. We investigated whether the Valsalva phase 2 diastolic blood pressure rise (DBPVM2l_rise) serves as a sympathetic marker and proposed enhanced neurovascular transduction as a pathophysiological mechanism in hyperadrenergic POTS.

Methods

We included 21 POTS women and 22 healthy women to perform Valsalva and microneurography. MSNA spike rate was obtained using stationary wavelet transformation. The DBPVM2l_rise cut point for hyperadrenergic POTS was optimized by the golden section search with its correlation to phase 2 MSNA spike rate as an objective function. We defined peripheral sympathetic neurovascular transduction (psNVT) as a ratio of DBPVM2l_rise to early phase 2 MSNA increase. We compared Valsalva responses between the identified hyperadrenergic and non-hyperadrenergic POTS.

Results

The DBPVM2l_rise strongly correlated with the Valsalva phase 2 MSNA spike rate percentage change from baseline in healthy (r = 0.874, p < 0.001). The DBPVM2l_rise cutoff criterion of 15 mmHg optimally separated POTS into 7 hyperadrenergic (≥ 15 mmHg, r = 0.902, p = 0.014) and 14 non-hyperadrenergic (< 15 mmHg, r = 0.629, p = 0.021). Although similar MSNA spike rate, the hyperadrenergic group had higher baseline systolic blood pressure (118 ± 10 vs 105 ± 12 mmHg, p = 0.026), shorter pressure recovery time (1.15 ± 0.75 vs 2.59 ± 1.17 s, p = 0.048), and higher psNVT (2.60 ± 1.02 vs 0.58 ± 0.46 mmHg/spike·s−1, p < 0.001) than the non-hyperadrenergic POTS.

Conclusion

DBPVM2l_rise ≥ 15 mmHg could be a sympathetic clinical marker and could identify hyperadrenergic POTS, characterized by enhanced neurovascular transduction despite comparable MSNA levels. This novel pathophysiological insight underscores the importance of sympathetic markers in POTS clinical management.